<!DOCTYPE html><html><head><title>The use of magnetic resonance imaging in the obstetric patient.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Guideline Title
</h3>
<div class='FieldValue'>
<div class="content_title">The use of magnetic resonance imaging in the obstetric patient.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Patenaude Y, Pugash D, Lim K, Morin L, Diagnostic Imaging Committee, Lim K, Bly S, Butt K, Cargill Y, Davies G, Denis N, Hazlitt G, Morin L, Naud K, Ouellet A, Salem S. The use of magnetic resonance imaging in the obstetric patient. J Obstet Gynaecol Can. 2014 Apr;36(4):349-55. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=24798674" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Recommendations
</h2>
<div class='field field_text'>
<h3>
Major Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The quality of evidence assessment (<strong>I-III</strong>) and classification of recommendations (<strong>A-E, L</strong>) are defined at the end of the "Major Recommendations" field.</p>
<p><strong>Summary Statements</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Fetal magnetic resonance imaging (MRI) is safe at 3.0 tesla or less during the second and third trimesters. (<strong>II-2</strong>) </li>
    <li>It is safe to continue breastfeeding after receiving a gadolinium contrast agent. (<strong>III</strong>) </li>
</ol>
<p><strong>Recommendations</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Use of MRI during the first trimester of pregnancy should be restricted to maternal indications for which the information is considered clinically imperative. Inadvertent exposure to magnetic resonance imaging during the first trimester has not been associated with any long-term sequelae and should not raise clinical concern. (<strong>III-C</strong>) </li>
    <li>Gadolinium contrast may be used in pregnant women when the benefits outweigh the potential risks. (<strong>III-C</strong>) </li>
</ol>
<p><span style="text-decoration: underline;"><strong>Definitions</strong></span>:</p>
<p><strong>Quality of Evidence Assessment*</strong></p>
<p><strong>I</strong>: Evidence obtained from at least one properly randomized controlled trial</p>
<p><strong>II-1</strong>: Evidence from well-designed controlled trials without randomization</p>
<p><strong>II-2</strong>: Evidence from well-designed cohort (prospective or retrospective) or case&ndash;control studies, preferably from more than one centre or research group</p>
<p><strong>II-3</strong>: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category</p>
<p><strong>III</strong>: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees</p>
<p class="Note">*Adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.</p>
<p><strong>Classification of Recommendations&dagger;</strong></p>
<p><strong>A</strong>. There is good evidence to recommend the clinical preventive action</p>
<p><strong>B</strong>. There is fair evidence to recommend the clinical preventive action</p>
<p><strong>C</strong>. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making</p>
<p><strong>D</strong>. There is fair evidence to recommend against the clinical preventive action</p>
<p><strong>E</strong>. There is good evidence to recommend against the clinical preventive action</p>
<p><strong>L</strong>. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making</p>
<p class="Note">&dagger;Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Clinical Algorithm(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None provided</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Scope
</h2>
<div class='field field_text'>
<h3>
Disease/Condition(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Conditions requiring magnetic resonance imaging (MRI) during pregnancy</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Guideline Category
</h3>
<div class='FieldValue'>
Diagnosis
</div>
<div class='FieldValue'>
Evaluation
</div>
<div class='FieldValue'>
Technology Assessment
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Clinical Specialty
</h3>
<div class='FieldValue'>
Obstetrics and Gynecology
</div>
<div class='FieldValue'>
Radiology
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Intended Users
</h3>
<div class='FieldValue'>
Allied Health Personnel
</div>
<div class='FieldValue'>
Health Care Providers
</div>
<div class='FieldValue'>
Health Plans
</div>
<div class='FieldValue'>
Hospitals
</div>
<div class='FieldValue'>
Physician Assistants
</div>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Objective(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>To review the biological effects and safety of magnetic resonance imaging (MRI) in the obstetric patient and to review procedural issues, indications, and contraindications for obstetrical MRI</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Target Population
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Pregnant and postnatal women</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Interventions and Practices Considered
</h3>
<div class='FieldValue'>
<ol style="list-style-type: decimal;" start="1">
    <li>Obstetrical magnetic resonance imaging (MRI) in first trimester (restricted to clinically imperative indications) </li>
    <li>Use of gadolinium contrast agents (if benefits outweigh risks) </li>
</ol>
</div>

</div>
<div class='field field_text'>
<h3>
Major Outcomes Considered
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Establishment of a framework for obstetrical magnetic resonance imaging (MRI) use </li>
    <li>Patient and clinician assurance of obstetrical MRI safety </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Methodology
</h2>
<div class='field field_picklist-many'>
<h3>
Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
Searches of Electronic Databases
</div>
<div class='FieldValue'>
Searches of Unpublished Data
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Published literature was retrieved through searches of PubMed or MEDLINE in 2013 using controlled vocabulary and key words (e.g., MRI, safety, pregnancy). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies published in English and in French. There were no date restrictions. Searches were updated on a regular basis and incorporated in the guideline to July 2013. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Number of Source Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Assess the Quality and Strength of the Evidence
</h3>
<div class='FieldValue'>
Weighting According to a Rating Scheme (Scheme Given)
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Quality of Evidence Assessment</strong>*</p>
<p><strong>I</strong>: Evidence obtained from at least one properly randomized controlled trial</p>
<p><strong>II-1</strong>: Evidence from well-designed controlled trials without randomization</p>
<p><strong>II-2</strong>: Evidence from well-designed cohort (prospective or retrospective) or case&ndash;control studies, preferably from more than one centre or research group</p>
<p><strong>II-3</strong>: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category</p>
<p><strong>III</strong>: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees</p>
<p class="Note">*Adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
Systematic Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of the Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care (see the "Rating Scheme for the Strength of the Evidence" field).</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
Expert Consensus
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Classification of Recommendations&dagger;</strong></p>
<p><strong>A</strong>. There is good evidence to recommend the clinical preventive action</p>
<p><strong>B</strong>. There is fair evidence to recommend the clinical preventive action</p>
<p><strong>C</strong>. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making</p>
<p><strong>D</strong>. There is fair evidence to recommend against the clinical preventive action</p>
<p><strong>E</strong>. There is good evidence to recommend against the clinical preventive action</p>
<p><strong>L</strong>. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making</p>
<p class="Note">&dagger;Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Cost Analysis
</h3>
<div class='FieldValue'>
<div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Method of Guideline Validation
</h3>
<div class='FieldValue'>
Internal Peer Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of Method of Guideline Validation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This clinical practice guideline has been prepared by the Diagnostic Imaging Committee, reviewed by the Family Physician Advisory Committee, and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Recommendations
</h2>
<div class='field field_text'>
<h3>
Type of Evidence Supporting the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Benefits/Harms of Implementing the Guideline Recommendations
</h2>
<div class='field field_text'>
<h3>
Potential Benefits
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Appropriate and safe use of magnetic resonance imaging (MRI) in the obstetrical patient</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Potential Harms
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Maternal risks associated with the use of magnetic resonance imaging (MRI) are the same as for non-pregnant patients. One safety consideration for the obstetrical patient is prolonged supine positioning. A gravid uterus of significant size can lead to hypotension due to compression of the inferior vena cava. This can be avoided by placing the patient in a lateral oblique or lateral decubitus position. </li>
    <li>Theoretical fetal concerns include teratogenic and biological effects. It is known that MRI may cause effects at the cellular level from the induction of local electric fields, currents from static and time-varying magnetic fields, and tissue and cellular heating from radiofrequency (RF) fields. </li>
    <li>To date there is insufficient evidence to understand the true risks of first trimester exposure to the developing fetus. Until these theoretical concerns can be appropriately addressed, the guideline developers advocate a cautious approach to using obstetrical MRI in the first trimester. </li>
    <li>Gadolinium crosses the placenta and is excreted by the fetal kidneys into the amniotic fluid, where it remains, exposing the developing fetus, particularly the lungs and gastrointestinal tract, for an extended period of time. The risks and benefits of gadolinium use must be discussed with the pregnant patient and referring clinician. Despite animal data and concerns about the use of gadolinium in pregnancy, there have been no reported adverse human fetal effects. However, many authors remain cautious about the use of gadolinium at any time in pregnancy. </li>
    <li>Obstetrical MRI can be technically challenging to perform and interpret given the movement of the fetus and its variable lie and presentation. The imaging protocol must be altered when the fetus moves or if new anomalies are detected in the course of the scan. </li>
    <li>Slice thickness between 2.5 and 5 mm is used in examining most fetal structures. Thinner slices are possible but have adverse effects on signal-to-noise ratio. At present, the minimum voxel size that may be obtained with fetal MRI is 0.8 &times; 0.8 &times; 2.5 mm, with slice thickness and fetal&ndash;maternal movement the major limiting factors. These factors decrease resolution and may obscure structures smaller than 1 mm and create difficulties in accurately measuring small or thin structures. </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Qualifying Statements
</h2>
<div class='field field_text'>
<h3>
Qualifying Statements
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the Society of Obstetricians and Gynaecologists of Canada (SOGC).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Implementation of the Guideline
</h2>
<div class='field field_text'>
<h3>
Description of Implementation Strategy
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An implementation strategy was not provided.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Implementation Tools
</h3>
<div class='FieldValue'>
Foreign Language Translations
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-many'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Getting Better
</div>
<div class='FieldValue'>
Staying Healthy
</div>

</div>
<div class='field field_picklist-many'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Patient-centeredness
</div>
<div class='FieldValue'>
Safety
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information and Availability
</h2>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Patenaude Y, Pugash D, Lim K, Morin L, Diagnostic Imaging Committee, Lim K, Bly S, Butt K, Cargill Y, Davies G, Denis N, Hazlitt G, Morin L, Naud K, Ouellet A, Salem S. The use of magnetic resonance imaging in the obstetric patient. J Obstet Gynaecol Can. 2014 Apr;36(4):349-55. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=24798674" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable. The guideline was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date Released
</h3>
<div class='FieldValue'>
2014 Apr
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Guideline Developer(s)
</h3>
<div class='FieldValue'>
Society of Obstetricians and Gynaecologists of Canada - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Source(s) of Funding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Society of Obstetricians and Gynaecologists of Canada (SOGC)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Committee
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Diagnostic Imaging Committee</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of Group That Authored the Guideline
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Principal Authors</em>: Yves Patenaude, MD, Sherbrooke QC; Denise Pugash, MD, Vancouver BC; Kenneth Lim, MD, Vancouver BC; Lucie Morin, MD, Montreal QC</p>
<p><em>Diagnostic Imaging Committee</em>: Kenneth Lim, MD (<em>Chair</em>), Vancouver BC; Stephen Bly, MD, Ottawa ON; Kimberly Butt, MD, Fredericton NB; Yvonne Cargill, MD, Ottawa ON; Gregory Davies, MD, Kingston ON; Nanette Denis, RDMS, CRGS, Saskatoon SK; Gail Hazlitt, RN, RDMS, Winnipeg MB; Lucie Morin, MD, Montreal QC; Kentia Naud, MD, Halifax NS; Annie Ouellet, MD, Sherbrooke QC; Shia Salem, MD, Toronto ON</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Disclosure statements have been received from all contributors.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href="http://sogc.org/guidelines/use-magnetic-resonance-imaging-obstetric-patient/" title="SOGC Web site">Society of Obstetricians and Gynaecologists of Canada (SOGC) Web site</a>. Also available in French from the <a href="http://sogc.org/fr/guidelines/utilisation-de-limagerie-par-resonance-magnetique-en-obstetrique/" title="SOGC Web site">SOGC Web site</a>.</p>
<p>Print copies: Available from the Society of Obstetricians and Gynaecologists of Canada, La soci&eacute;t&eacute; des obst&eacute;triciens et gyn&eacute;cologues du Canada (SOGC) 780 promenade Echo Drive Ottawa, ON K1S 5R7 (Canada); Phone: 1-800-561-2416.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Availability of Companion Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None available</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Patient Resources
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None available</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NGC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary was completed by ECRI Institute on May 19, 2014. The information was verified by the guideline developer on June 4, 2014.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NGC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>
</div>

</div>

</div>
</body></html>